Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 10/20 | 0.44 |
| ▸ | CDK1 | P06493 | 9/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.44 |
| ▸ | PI4KA | P42356 | 2/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384383 | 1.00 | PDPK1 (0.53) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL1982409 | 0.86 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL2402087 | 0.86 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL28144662 | 0.81 | PDPK1 (0.46) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL2306216 | 0.80 | POLA1 (0.46) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL1924592 | 0.80 | PDPK1 (0.59) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL29592683 | 0.80 | PDPK1 (0.59) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL30150749 | 0.80 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL19840 | 0.80 | PDPK1 (0.51) | PDPK1GDACDK2CDK1CCNB1 | |
| SCHEMBL16753033 | 0.80 | PNP (0.36) | PDPK1GDACDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13355 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| US-12215343-B2 | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-04 | — | — | US | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-4314297-A1 | TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE | Specific Biologics Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| CN-117083385-A | Targeting oncogenic mutations with double-cleaving endonucleases | 特定生物制品公司 | 2023-11-17 | — | — | CN | claimed |
| EP-4240839-A1 | GENE EDITING WITH A MODIFIED ENDONUCLEASE | Specific Biologics Inc. (CA) | 2023-09-13 | — | — | EP | claimed |
| CN-116669775-A | Gene editing with modified endonucleases | 特定生物制品公司 | 2023-08-29 | — | — | CN | claimed |
| US-8710023-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | claimed |
| US-20140080894-A1 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION | 2014-03-20 | — | — | US | claimed |
| WO-2012119051-A2 | ENHANCED BIODISTRIBUTION OF OLIGOMERS | GROOVE BIOPHARMA CORPORATION (US) | 2012-09-07 | — | — | WO | claimed |
| US-20120077866-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | claimed |
| US-8093224-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | claimed |
| US-20110117646-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7915231-B2 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-20090275133-A1 | ANTISENSE MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-20060024727-A1 | Antisense modulation of C-reactive protein expression | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | claimed |
| US-20040049022-A1 | Composition & methods for treatment and screening | NYCE JONATHAN W (US) | 2004-03-11 | — | — | US | claimed |